Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit

BUFFALO, NY, Nov 02 (MARKET WIRE) --
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company
is scheduled to present at the Merriman Curhan Ford 6th Annual Investor
Summit, November 10, in New York City.

Michael Fonstein, Ph.D., Chief Executive Officer and President of
Cleveland BioLabs, will give a presentation on November 10, at 3:00 p.m.
Eastern Standard Time. An audio webcast of the presentation may be
accessed at the Company's website, www.cbiolabs.com in the Investors
section. A replay of the presentation will be archived for 90 days after
the conference at the same location.

Cleveland BioLabs is developing a pipeline of products for multiple
defense and medical applications from two primary families of compounds:
Protectans and Curaxins. Protectans are being developed as drug
candidates that protect normal tissues from acute stresses such as
radiation and chemotherapy. Curaxins are being developed as anticancer
agents that could act as mono-therapy drugs or in combination with other
existing anticancer agents.

For more information about the Merriman Curhan Ford 6th Annual Investor
Summit, please refer to http://www.mcfco.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include
the "Risk Factors" described in the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March 30, 2009.

Contact:
Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com

Copyright 2009, Market Wire, All rights reserved.

-0-